Institut Gustave Roussy
39, rue Camille Desmoulins
4 articles with Institut Gustave Roussy
Gustave Roussy and Protagen AG Collaborate to Improve the Risk Profiling of Cancer Patients Undergoing Immunotherapy
Protagen AG and Gustave Roussy have today announced the start of a collaboration to utilize Protagen’s SeroTag® technology to help identify biomarkers that predict and monitor immune-related adverse events (irAEs) in cancer patients treated with checkpoint inhibitors.
Delcath Systems, Inc. Announces Agreement With Institut Gustave Roussy for Launch of Hepatic CHEMOSAT Delivery System in France
Treatment Interruption Fails Test in Gastrointestinal Stromal Tumors (GIST) , Institut Gustave Roussy Study
ExonHit Therapeutics Inc. and Institut Gustave Roussy Announce the Signing of a License Agreement for Novel Breast Cancer Diagnostic Assay